Impact RH360

Impact RH360 is a wholly owned nonprofit subsidiary of Medicines360 focused on expanding access to women’s reproductive health products in low- and middle-income countries. Its primary commercial product is AVIBELA, a levonorgestrel-releasing intrauterine system offered across parts of Africa, South and Southeast Asia, Central America, and the Caribbean. The organization works with NGO, social marketing, and distribution partners to support product registration, provider training, launch, and market access. Impact RH360 appears to function as a global access and supply vehicle rather than a discovery-stage biotech company, with activity centered on commercialization and public-health implementation of an established contraceptive product.